BeStock  
Stocks › Biotechnology › MAZE

Maze Therapeutics MAZE

US equityMarket cap rank #2785Biotechnology
$31.37 −$1.06 (-3.27%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $31.37 0.00%
Open$31.77
Prev close$32.43
Day range$30.88 – $32.80
Volume818.9K
Market cap$1.72B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership112.4%+3.17 pts vs. prior quarter
Institutions holding199-1 vs. prior quarter
Insider trades (recent)15 buys / 35 sellsNet selling
Short interest12.03% of floatDays to cover 8.8 · as of 30 Oct 2026
Short-sale volume share25.9%5-day average of daily volume

Short-sale volume as % of daily volume

10%20%29%38%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$6.55M (14 inflow days, 6 outflow days).

Net flow by order size, last 20 sessions

−$8.5MSuper+$1.9MBig+$1.2MMid+$6.1MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 40.3% of shares outstanding.

Largest holders

  • Third Rock Ventures, LLC9.92%
  • Frazier Life Sciences Management, LP9.20%
  • Arch Venture Partners, L.P.7.53%
  • Deep Track Capital, LP6.83%
  • BlackRock6.79%
  • Janus Henderson Group plc6.23%
  • T. Rowe Price Group, Inc.5.00%
  • Logos Global Management, L.P.3.54%

By investor type

  • VC/PE Fund47.19%
  • Mutual Fund40.32%
  • Hedge Fund19.38%
  • Public Company4.60%
  • Individual/Insider0.75%
  • Private Company0.40%
  • Government Pension Fund0.16%
  • Endowment Fund0.16%

Reported short interest has risen from 10.78% to 12.03% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
BNP Paribas Financial Markets SNC Private Company 2026/Q3 +542,858 1.1%
J.P. Morgan Asset Management, Inc. Mutual Fund 2026/Q3 +243,482 2.1%
BlackRock Mutual Fund 2026/Q3 +209,829 6.8%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +2,613,857 5.0%
Braidwell LP Hedge Fund 2026/Q3 +1,140,040 2.1%
BlackRock Mutual Fund 2026/Q3 +932,416 6.3%
J.P. Morgan Asset Management, Inc. Mutual Fund 2026/Q3 +886,028 1.7%
Farallon Capital Management, L.L.C. Hedge Fund 2026/Q3 +734,814 2.0%
Logos Global Management, L.P. Hedge Fund 2026/Q3 +700,000 3.5%
Marshall Wace LLP Hedge Fund 2026/Q3 +603,933 1.7%
Frazier Life Sciences Management, LP VC/PE Fund 2026/Q3 +465,641 9.2%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +411,504 3.6%
State Street Global Advisors Mutual Fund 2026/Q3 +360,811 1.8%
Driehaus Capital Management LLC Mutual Fund 2026/Q3 +318,724 1.7%
ADAR1 Capital Management, LLC Hedge Fund 2026/Q3 +289,181 0.6%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
1 Nov 2026 Jason Coloma Chief Executive Officer Automatic Disposition -34,501 $31.05 199,866
28 Oct 2026 Atul Dandekar Chief Strategy & Business Officer Derivative Exercise and Sale -7,500 $32.07 32,316
30 Sep 2026 Jason Coloma Chief Executive Officer Automatic Disposition -34,501 $27.02 234,367
30 Sep 2026 Harold Bernstein President of Research & Development and Chief Medical Officer Derivative Exercise and Sale -16,141 $26.93 –
28 Sep 2026 Atul Dandekar Chief Strategy & Business Officer Derivative Exercise and Sale -7,500 $27.06 32,316
3 Sep 2026 Harold Bernstein President of Research & Development and Chief Medical Officer Automatic Disposition -9,705 $26.22 –
2 Sep 2026 Jason Coloma Chief Executive Officer Open Market Disposition -22,638 $27.12 268,868
2 Sep 2026 Atul Dandekar Chief Strategy & Business Officer Open Market Disposition -6,434 $27.12 32,316
2 Sep 2026 Courtney Phillips General Counsel Open Market Disposition -3,993 $27.12 7,007
2 Sep 2026 Harold Bernstein President of Research & Development and Chief Medical Officer Open Market Disposition -10,295 $27.12 9,705
1 Sep 2026 Courtney Phillips General Counsel Intent to Sell (Form 144) -4,144 $26.54 –
1 Sep 2026 Harold Bernstein President of Research & Development and Chief Medical Officer Intent to Sell (Form 144) -10,685 $26.53 –
31 Aug 2026 Jason Coloma Chief Executive Officer Automatic Disposition -34,501 $26.31 291,506
31 Aug 2026 Jason Coloma Chief Executive Officer Derivative Exercise and Retained +50,000 – 291,506
31 Aug 2026 Atul Dandekar Chief Strategy & Business Officer Derivative Exercise and Retained +12,500 – 38,750
31 Aug 2026 Courtney Phillips General Counsel Derivative Exercise and Retained +11,000 – 11,000
31 Aug 2026 Harold Bernstein President of Research & Development and Chief Medical Officer Derivative Exercise and Sale -16,141 $26.36 20,000
31 Aug 2026 Harold Bernstein President of Research & Development and Chief Medical Officer Derivative Exercise and Retained +20,000 – 20,000
27 Aug 2026 Atul Dandekar Chief Strategy & Business Officer Derivative Exercise and Sale -7,500 $27.58 26,250
12 Aug 2026 Paula Johnson Director Other Derivative Acquisition +36,000 $27.67 36,000

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 6,684,604 12.0% 8.8
15 Oct 2026 7,527,939 13.6% 10.1
30 Sep 2026 6,565,330 11.8% 6.1
15 Sep 2026 5,678,289 10.2% 10.4
31 Aug 2026 5,918,321 10.7% 16.0
14 Aug 2026 5,988,933 10.8% 16.2

Discussion

No comments yet — be the first to weigh in on MAZE.

Sign in to join the discussion.

Scroll to Top